Cohance Lifesciences is set to invest Rs 110 crore in expanding its facilities in Hyderabad, India, and New Jersey, USA. 

The investment includes $10 million (approx. ₹87 crore) for enhancing its cGMP bioconjugation capabilities at its US subsidiary, NJ Bio. 

Additionally, Rs 23 crore will be invested in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad. 

This strategic expansion will allow Cohance to scale up high-value chemistries and strengthen its position as a key partner for global innovators in the rapidly growing field of next-generation therapeutics